PMID- 34421593
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210824
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Trigonelline, An Alkaloid From Leonurus japonicus Houtt., Suppresses Mast Cell 
      Activation and OVA-Induced Allergic Asthma.
PG  - 687970
LID - 10.3389/fphar.2021.687970 [doi]
LID - 687970
AB  - Trigonelline, one of the active compounds from Leonurus japonicus Houtt., has 
      been proven to have pharmacological value in diabetes, the central nervous system 
      and cardiovascular diseases. Recent studies have shown that it may also be 
      beneficial in controlling inflammation. However, the mechanism of the 
      antiallergic effects of trigonelline has not been well studied. As the key 
      effector cells participating in the development of allergies, mast cells have 
      been linked to the pathogenesis of asthma for ages. In this study, we 
      demonstrated the inhibitory effect of trigonelline on activated bone 
      marrow-derived mast cells (BMMCs) and verified its anti-inflammatory properties 
      using an ovalbumin (OVA)-induced asthma model. Trigonelline suppressed BMMC 
      degranulation and decreased the production of the cytokines, prostaglandin D(2) 
      (PGD(2)) and leukotriene C(4) (LTC(4)) in a dose-dependent manner. The potent 
      mechanism is mainly through the suppression of the nuclear factor kappa B (NF-kappaB) 
      and mitogen-activated protein kinase (MAPK) signaling pathways. Trigonelline can 
      alleviate pathological damage in lung tissue and reduce the levels of serum 
      immunoglobulin E (IgE) and T helper 2 (Th2) cytokines. RNA-seq results revealed 
      the HIF-1alpha to be a potential target for the allergic reaction. Taken together, 
      our study demonstrated that trigonelline can inhibit allergic inflammation in 
      vitro and in vivo, which may provide a basis for novel anti-inflammatory drug 
      development.
CI  - Copyright (c) 2021 Zhang, Zhang, Chen, Zhang, Yuan, Xiao, Lu and Xu.
FAU - Zhang, Wenhui
AU  - Zhang W
AD  - School of Pharmacy, Shanghai University of Traditional Chinese Medicine, 
      Shanghai, China.
FAU - Zhang, Yingling
AU  - Zhang Y
AD  - School of Pharmacy, Shanghai University of Traditional Chinese Medicine, 
      Shanghai, China.
FAU - Chen, Simin
AU  - Chen S
AD  - School of Pharmacy, Shanghai University of Traditional Chinese Medicine, 
      Shanghai, China.
FAU - Zhang, Hong
AU  - Zhang H
AD  - School of Pharmacy, Shanghai University of Traditional Chinese Medicine, 
      Shanghai, China.
FAU - Yuan, Man
AU  - Yuan M
AD  - School of Pharmacy, Shanghai University of Traditional Chinese Medicine, 
      Shanghai, China.
FAU - Xiao, Lianbo
AU  - Xiao L
AD  - Institute of Arthritis Research, Shanghai Academy of Chinese Medical Sciences, 
      Guanghua Integrative Medicine Hospital, Shanghai, China.
FAU - Lu, Yue
AU  - Lu Y
AD  - School of Pharmacy, Shanghai University of Traditional Chinese Medicine, 
      Shanghai, China.
FAU - Xu, Hongxi
AU  - Xu H
AD  - School of Pharmacy, Shanghai University of Traditional Chinese Medicine, 
      Shanghai, China.
AD  - Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20210804
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8371462
OTO - NOTNLM
OT  - Leonurus japonicus Houtt
OT  - allergic asthma
OT  - inflammatory
OT  - mast cells
OT  - trigonelline
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/08/24 06:00
MHDA- 2021/08/24 06:01
PMCR- 2021/08/04
CRDT- 2021/08/23 06:25
PHST- 2021/03/30 00:00 [received]
PHST- 2021/05/27 00:00 [accepted]
PHST- 2021/08/23 06:25 [entrez]
PHST- 2021/08/24 06:00 [pubmed]
PHST- 2021/08/24 06:01 [medline]
PHST- 2021/08/04 00:00 [pmc-release]
AID - 687970 [pii]
AID - 10.3389/fphar.2021.687970 [doi]
PST - epublish
SO  - Front Pharmacol. 2021 Aug 4;12:687970. doi: 10.3389/fphar.2021.687970. 
      eCollection 2021.